Skip to content
Head to head

Alpha Tau Medical vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: DRTS · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

DRTS +208.5%VRTX +18.7%
It’s close.
DRTSVRTX
Snapshot
Sector--Biotechnology
Last price11.76515.02
Change today+3.93%-1.08%
1-year return+238.8%+22.0%
Market cap$1.09B$130.58B
52-week range3.65 – 15.79412.27 – 568.67
Valuation
P/E (TTM)-11.3033.14
P/E percentile, own 5-yr range32nd99th
P/B24.646.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-0.5315.32
Net profit (TTM)$-48.94M$3.88B
Revenue (TTM)$0$12.95B
Provider revenue period date2026-06-292026-09-29
Revenue growth (YoY)--+11.8%
Gross margin--85.5%
Operating margin--33.1%
Net margin--30.7%
Free cash flow (TTM)--$3.20B
Provider cash-flow period date2022-06-292026-09-29
Ownership & sentiment
Institutional ownership27.3%96.8%
Insider activity (12mo)0 buy / 16 sell28 buy / 22 sell
Short interest (% of float)4.2%1.9%
Analyst consensus100% buy (3)95% buy / 5% hold (21)
Analyst price target$23 (+93%)$624 (+21%)
StockVane view
StockVane Quant RatingC (100)C (68)
Company
Employees1216,400
Founded20151989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.